外泌体在心力衰竭发生发展中的作用及临床价值

doi:10.3969/j.issn.1004-583X.2024.03.011

摘要/Abstract

摘要：

心力衰竭(heart failure,HF)是各种心血管疾病的终末阶段,具有较高的发病率以及致死率。外泌体可以通过影响肾素-血管紧张素系统、心肌纤维化、心肌细胞凋亡、新生血管生成等多方面参与HF的发生与发展。外泌体不但可以作为HF的诊断标志物,而且能够作为靶向药物递送或干细胞治疗的载体助力于HF的治疗。本文就外泌体在HF发生发展中的作用、诊断以及治疗研究进展进行综述。

关键词: 外泌体, 心力衰竭, 机制, 诊断, 治疗

中图分类号:

R329.24

孙庆, 王海龙, 米庆, 乐暾, 牟华明. 外泌体在心力衰竭发生发展中的作用及临床价值[J]. 临床荟萃, 2024, 39(3): 259-263.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2024.03.011

https://www.lchc.cn/CN/Y2024/V39/I3/259

图/表 2

参考文献 40

[1]	Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: A report of the heart failure society of america, heart failure association of the european society of cardiology, japanese heart failure society and writing committee of the universal definition of heart failure[J]. J Card Fail, 2021, Mar1:S1071- 9164(21)00050-6. Online ahead of print
[2]	《中国心血管健康与疾病报告》编写组. 《中国心血管健康与疾病报告2021》概述[J]. 中国心血管病研究, 2022, 20(7): 577-596.
[3]	Li H, Gu J, Sun X, et al. Isolation of swine bone marrow lin-/CD45-/CD133+ cells and cardio-protective effects of its exosomes[J]. Stem Cell Rev Rep, 2023, 19(1): 213-229.
[4]	Luo Z, Hu X, Wu C, et al. Plasma exosomes generated by ischaemic preconditioning are cardioprotective in a rat heart failure model[J]. Br J Anaesth, 2023, 130(1): 29-38.
[5]	Femminò S, Penna C, Margarita S, et al. Extracellular vesicles and cardiovascular system: Biomarkers and cardioprotective effectors[J]. Vascul Pharmacol, 2020, 135:106790.
[6]	Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes[J]. Science, 2020, 367(6478):eaau6977.
[7]	Yao J, Huang K, Zhu D, et al. A minimally invasive exosome spray repairs heart after myocardial infarction[J]. ACS Nano, 2021, 15(7): 11099-11111. doi: 10.1021/acsnano.1c00628 pmid: 34152126
[8]	Lyu L, Wang H, Li B, et al. A critical role of cardiac fibroblast-derived exosomes in activating renin angiotensin system in cardiomyocytes[J]. J Mol Cell Cardiol, 2015, 89(Pt B): 268-279. doi: 10.1016/j.yjmcc.2015.10.022 pmid: 26497614
[9]	Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy[J]. J Clin Invest, 2014, 124(5): 2136-2146. doi: 10.1172/JCI70577 pmid: 24743145
[10]	Xiao M, Zeng W, Wang J, et al. Exosomes protect against acute myocardial infarction in rats by regulating the renin-angiotensin system[J]. Stem Cells Dev, 2021, 30(12): 622-631.
[11]	Moita MR, Silva MM, Diniz C, et al. Transcriptome and proteome profiling of activated cardiac fibroblasts supports target prioritization in cardiac fibrosis[J]. Front Cardiovasc Med, 2022, 9:1015473.
[12]	何亚州. 温中益气方对来源于外泌体的miR-320a调控PIK3CA防治慢性心力衰竭心肌纤维化的研究[D]. 南宁: 广西中医药大学, 2019.
[13]	Li J, Salvador AM, Li G, et al. Mir-30d regulates cardiac remodeling by intracellular and paracrine signaling[J]. Circ Res, 2021, 128(1): e1-e23.
[14]	Vaskova E, Ikeda G, Tada Y, et al. Sacubitril/valsartan improves cardiac function and decreases myocardial fibrosis via downregulation of exosomal mir-181a in a rodent chronic myocardial infarction model[J]. J Am Heart Assoc, 2020, 9(13): e015640.
[15]	Luther KM, Haar L, McGuinness M, et al. Exosomal miR-21a-5p mediates cardioprotection by mesenchymal stem cells[J]. J Mol Cell Cardiol, 2018, 119:125-137. doi: S0022-2828(18)30140-8 pmid: 29698635
[16]	Gao L, Qiu F, Cao H, et al. Therapeutic delivery of microRNA-125a-5p oligonucleotides improves recovery from myocardial ischemia/reperfusion injury in mice and swine[J]. Theranostics, 2023, 13(2): 685-703. doi: 10.7150/thno.73568 pmid: 36632217
[17]	Hou Z, Qin X, Hu Y, et al. Longterm exercise-derived exosomal miR-342-5p: A novel exerkine for cardioprotection[J]. Circ Res, 2019, 124(9): 1386-1400. doi: 10.1161/CIRCRESAHA.118.314635 pmid: 30879399
[18]	Sun C, Li W, Li Y, et al. MiR-182-5p mediated by exosomes derived from bone marrow mesenchymal stem cell attenuates inflammatory responses by targeting tlr4 in a mouse model of myocardial infraction[J]. Immune Netw, 2022, 22(6): e49.
[19]	Hu C, Liao J, Huang R, et al. MicroRNA-155-5p in serum derived-exosomes promotes ischaemia-reperfusion injury by reducing CypD ubiquitination by NEDD4[J]. ESC Heart Fail, 2023, 10(2):1144-1157. doi: 10.1002/ehf2.14279 pmid: 36631006
[20]	Ranjan P, Kumari R, Goswami SK, et al. Myofibroblast-derived exosome induce cardiac endothelial cell dysfunction[J]. Front Cardiovasc Med, 2021, 8:676267.
[21]	Qiao L, Hu S, Liu S, et al. MicroRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential[J]. J Clin Invest, 2019, 129(6): 2237-2250. doi: 10.1172/JCI123135 pmid: 31033484
[22]	Liu H, Zhang Y, Yuan J, et al. Dendritic cell-derived exosomal miR-494-3p promotes angiogenesis following myocardial infarction[J]. Int J Mol Med, 2021, 47(1): 315-325.
[23]	李光召. 肥厚心肌细胞来源外泌体miR-29a调控内皮细胞血管新生机制的研究[D]. 珠海: 遵义医科大学, 2020.
[24]	Liu S, Chen J, Shi J, et al. M1-like macrophage-derived exosomes suppress angiogenesis and exacerbate cardiac dysfunction in a myocardial infarction microenvironment[J]. Basic Res Cardiol, 2020, 115(2): 22.
[25]	Wu T, Chen Y, Du Y, et al. Circulating exosomal miR-92b-5p is a promising diagnostic biomarker of heart failure with reduced ejection fraction patients hospitalized for acute heart failure[J]. J Thorac Dis, 2018, 10(11): 6211-6220. doi: 10.21037/jtd.2018.10.52 pmid: 30622793
[26]	Wang L, Liu J, Xu B, et al. Reduced exosome miR-425 and miR-744 in the plasma represents the progression of fibrosis and heart failure[J]. Kaohsiung J Med Sci, 2018, 34(11): 626-633.
[27]	Lu W, Liu X, Zhao L, et al. MiR-22-3p in exosomes increases the risk of heart failure after down-regulation of FURIN[J]. Chem Biol Drug Des, 2023, 101(3):550-567.
[28]	Xie Y, Hang JZ, Zhang N, et al. Clinical significance of MiR-27a expression in serum exosomes in patients with heart failure[J]. Cell Mol Biol (Noisy-le-grand), 2022, 67(5): 324-331. doi: 10.14715/cmb/2021.67.5.44 pmid: 35818236
[29]	赵娟, 刘婷, 魏红, 等. 血浆外泌体微小RNA-206和N末端B型脑钠肽前体及同型半胱氨酸在心力衰竭患者中的表达水平及应用价值[J]. 中国医药, 2022, 17(9): 1326-1330.
[30]	孙晓燕, 亓良森, 赵海鸿, 等. 血清外泌体miR-122及miR-194在心肌梗死患者中诊断早期心衰的价值[J]. 解放军医学院学报, 2021, 42(9): 940-945.
[31]	Matsumoto S, Sakata Y, Suna S, et al. Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction[J]. Circ Res, 2013, 113(3): 322-326. doi: 10.1161/CIRCRESAHA.113.301209 pmid: 23743335
[32]	Mentkowski KI, Lang JK. Exosomes engineered to express a cardiomyocyte binding peptide demonstrate improved cardiac retention in vivo[J]. Sci Rep, 2019, 9(1): 10041.
[33]	Yan F, Cui W, Chen Z. Mesenchymal stem cell-derived exosome-loaded microRNA-129-5p inhibits TRAF3 expression to alleviate apoptosis and oxidative stress in heart failure[J]. Cardiovasc Toxicol, 2022, 22(7): 631-645. doi: 10.1007/s12012-022-09743-9 pmid: 35546649
[34]	Xiong Y, Tang R, Xu J, et al. Tongxinluo-pretreated mesenchymal stem cells facilitate cardiac repair via exosomal transfer of miR-146a-5p targeting IRAK1/NF-κB p65 pathway[J]. Stem Cell Res Ther, 2022, 13(1): 289.
[35]	Gao L, Wang L, Wei Y, et al. Exosomes secreted by hiPSC-derived cardiac cells improve recovery from myocardial infarction in swine[J]. Sci Transl Med, 2020, 12(561):eaay1318.
[36]	Davidson SM, Riquelme JA, Zheng Y, et al. Endothelial cells release cardioprotective exosomes that may contribute to ischaemic preconditioning[J]. Sci Rep, 2018, 8(1): 15885.
[37]	Li Q, Huang Z, Wang Q, et al. Targeted immunomodulation therapy for cardiac repair by platelet membrane engineering extracellular vesicles via hitching peripheral monocytes[J]. Biomaterials, 2022, 284:121529.
[38]	Cheng G, Zhu D, Huang K, et al. Minimally invasive delivery of a hydrogel-based exosome patch to prevent heart failure[J]. J Mol Cell Cardiol, 2022, 169:113-121. doi: 10.1016/j.yjmcc.2022.04.020 pmid: 35523270
[39]	Poupardin R, Wolf M, Strunk D. Adherence to minimal experimental requirements for defining extracellular vesicles and their functions[J]. Adv Drug Deliv Rev, 2021, 176:113872.
[40]	Kim JY, Rhim WK, Yoo YI, et al. Defined MSC exosome with high yield and purity to improve regenerative activity[J]. J Tissue Eng, 2021, 12:20417314211008626.

外泌体在心力衰竭发生发展中的作用及临床价值

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 2

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李慧丹, 睢国鑫, 赵娟, 杨涛. 心电图参数联合血清NT-proBNP、25-OH-VitD3水平预测慢性心力衰竭患者主要心血管不良事件的价值[J]. 临床荟萃, 2026, 41(7): 590-595.
[2]	夏宁宁, 吴以龙, 杨沱, 林钦棋, 林卫星, 林敏. 胆道子镜辅助内镜逆行阑尾炎治疗术治疗急慢性阑尾炎27例临床分析[J]. 临床荟萃, 2026, 41(7): 596-601.
[3]	朱洪银, 严丹, 肖志原, 杨盼. 大剂量普瑞巴林中毒的临床救治与转归1例[J]. 临床荟萃, 2026, 41(7): 642-647.
[4]	张天娇, 宋菲, 由佳鹭, 金雨佳, 孙妍. 肝癌细胞上皮-间质转化中微小RNA通路调控的研究进展[J]. 临床荟萃, 2026, 41(7): 659-667.
[5]	欧阳芊, 赵颖, 孟珩, 徐安定. 缺血性卒中急性期的抗血小板治疗[J]. 临床荟萃, 2026, 41(6): 485-492.
[6]	赵丹, 杨亚莉, 张志强. 结直肠癌患者外泌体miR-23b、miR-152-3p表达水平及其对预后的预测价值[J]. 临床荟萃, 2026, 41(6): 516-521.
[7]	张艳丽, 赵朕华, 张敬知, 孟庆顺. 抗整合素抗体αvβ6在溃疡性结肠炎诊断中的应用[J]. 临床荟萃, 2026, 41(6): 568-571.
[8]	周颖, 周芳芳. 急性肾损伤新型生物标志物的研究进展[J]. 临床荟萃, 2026, 41(5): 475-480.
[9]	李鑫月, 李世豪, 刘娜, 吴婧, 李美玲, 刘改芳. CC趋化因子配体调控胃癌的研究现状及进展[J]. 临床荟萃, 2026, 41(4): 363-368.
[10]	刘一坤, 张明, 刘倩, 孙绍婷, 李媛媛, 杜书同. 连续性肾脏替代治疗在脓毒症合并急性肾损伤中的研究进展[J]. 临床荟萃, 2026, 41(4): 374-379.
[11]	祝孟丽, 李敏, 薛莎莎, 蔚苗苗, 付慧娟. 基于机器学习整合多维危险因素的急性失代偿性心力衰竭患者再住院风险预测模型[J]. 临床荟萃, 2026, 41(3): 205-211.
[12]	姜俊辰, 郭蓉娟, 张帆, 刘佳霖. MAPK信号通路在脑出血中的研究进展[J]. 临床荟萃, 2026, 41(3): 269-273.
[13]	刘栋, 杨启昌, 李欣然. 抑郁症与肠道菌群关联性的研究进展及趋势分析[J]. 临床荟萃, 2026, 41(3): 285-288.
[14]	张艳萍, 李坷, 张壮. 心房颤动相关急性脑梗死早期启动抗凝治疗的安全性[J]. 临床荟萃, 2026, 41(2): 116-121.
[15]	曹乐, 赵宇鹏, 薛凌. 系统免疫炎症指数对射血分数降低型心衰患者发生主要不良心血管事件的预测价值[J]. 临床荟萃, 2026, 41(2): 122-127.